多伦多肝细胞癌风险指数:预测肝硬化患者10年肝细胞癌风险的经验证评分系统
该研究通过回顾性病历复习建立肝硬化患者队列,按病因计算肝细胞癌(HCC)发病率,利用多变量Cox回归建立多伦多HCC风险指数(THRI),并在外部队列中验证。THRI对肝硬化患者HCC具有良好预测能力,可能有助于指导HCC监测建议。
要点
- 肝硬化患者10年HCC累积发病率因病因不同差异显著,病毒性肝炎为22%,脂肪性肝炎为16%,自身免疫性肝病为5%(p<0.001)。
- THRI根据年龄、性别、病因和血小板计数赋值,低危(<120分)、中危(120-240分)和高危(>240分)组的10年HCC累积发病率分别为3%、10%和32%。
- THRI在外部验证队列(n=1,144)中预测能力相似,Harrell's c统计量为0.77。
核心结论
- 肝硬化患者HCC发病率因病因不同而显著不同。
- THRI使用常规可得的临床和实验室参数,对肝硬化患者HCC具有良好预测能力,并已在外部队列中得到验证。
- 该风险评分可能有助于指导肝硬化患者HCC监测的建议。
研究设计与样本
- 通过回顾性病历复习确定经活检或非侵入性方法诊断的肝硬化患者作为衍生队列。
- 衍生队列纳入2,079例肝硬化且随访≥6个月的患者,其中226例(10.8%)发生HCC。
- 外部验证队列纳入原发性胆汁性肝硬化、乙型肝炎病毒肝硬化和丙型肝炎病毒肝硬化患者(n=1,144)。
主要发现
- 10年HCC累积发病率因病因不同而异:病毒性肝炎患者为22%,脂肪性肝炎患者为16%,自身免疫性肝病患者为5%(p<0.001)。
- 多变量Cox回归显示,年龄、性别、病因和血小板与HCC相关。
- 10年HCC累积发病率在低危(<120分)、中危(120-240分)和高危(>240分)组分别为3%、10%和32%,内部验证后数值保持一致。
- 外部验证中THRI预测能力与衍生队列相似,Harrell's c统计量为0.77。
关键数值与推荐
- THRI根据年龄、性别、病因和血小板计数的风险比比例赋值。
- 低危组定义为<120分,中危组为120-240分,高危组为>240分。
- 低危、中危和高危组的10年HCC累积发病率分别为3%、10%和32%。
临床怎么用
- THRI使用常规可得的临床和实验室参数,可能有助于指导肝硬化患者HCC监测的建议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Current guidelines recommend biannual surveillance for hepatocellular carcinoma (HCC) in all patients with cirrhosis, regardless of etiology. However, HCC incidence is not well established for many causes of cirrhosis. We aimed to assess the disease-specific incidence of HCC in a large cohort of patients with cirrhosis and to develop a scoring system to predict HCC risk. METHODS: A derivation cohort of patients with cirrhosis diagnosed by biopsy or non-invasive measures was identified through retrospective chart review. The disease-specific incidence of HCC was calculated according to etiology of cirrhosis. Factors associated with HCC were identified through multivariable Cox regression and used to develop a scoring system to predict HCC risk. The scoring system was evaluated in an external cohort for validation. RESULTS: Of 2,079 patients with cirrhosis and ≥6months follow-up, 226 (10.8%) developed HCC. The 10-year cumulative incidence of HCC varied by etiologic category from 22% in patients with viral hepatitis, to 16% in those with steatohepatitis and 5% in those with autoimmune liver disease (p<0.001). By multivariable Cox regression, age, sex, etiology and platelets were associated with HCC. Points were assigned in proportion to each hazard ratio to create the Toronto HCC Risk Index (THRI). The 10-year cumulative HCC incidence was 3%, 10% and 32% in the low-risk (<120points), medium-risk (120-240) and high-risk (>240) groups respectively, values that remained consistent after internal validation. External validation was performed on a cohort of patients with primary biliary cirrhosis, hepatitis B viral and hepatitis C viral cirrhosis (n=1,144), with similar predictive ability (Harrell's c statistic 0.77) in the validation and derivation cohorts. CONCLUSION: HCC incidence varies markedly by etiology of cirrhosis. The THRI, using readily available clinical and laboratory parameters, has good predictive ability for HCC in patients with cirrhosis, and has been validated in an external cohort. This risk score may help to guide recommendations regarding HCC surveillance among patients with cirrhosis. LAY SUMMARY: HCC incidence varies markedly depending on the underlying cause of cirrhosis. Herein, using readily available clinical and laboratory parameters we describe a risk score, THRI, which has a good predictive ability for HCC in patients with cirrhosis, and has been validated in an external cohort. This risk score may help to guide recommendations regarding HCC surveillance among patients with cirrhosis.
引用
- Sharma SA, Kowgier M, Hansen BE, et al. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol. 2017. PMID: 28844936. doi:10.1016/j.jhep.2017.07.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。